Cryptococcus neoformans blood stream infection in severe COVID-19 pneumonia

Rama V Thyagarajan1,2, Kristin E Mondy1,2, Dusten T Rose1

  • 1Dell Seton Medical Center at the University of Texas, USA.

Idcases
|September 6, 2021
PubMed

Insights

Severe COVID-19 pneumonia can lead to serious complications. This case highlights the potential for fungal infections, like Cryptococcus neoformans, to reactivate and worsen outcomes in patients with critical coronavirus disease.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Severe coronavirus disease (COVID-19) is frequently associated with pneumonia and acute respiratory distress syndrome.
  • Fungal coinfections are increasingly recognized as a contributor to mortality in severe COVID-19 patients.
  • Aspergillus ventilator-associated pneumonia is a known complication in critically ill patients.

Observation:

  • A patient with severe COVID-19 developed pneumonia.
  • The patient had a likely reactivation of community-acquired *Cryptococcus neoformans*.

Findings:

  • This case suggests that *Cryptococcus neoformans* reactivation can occur in the context of severe COVID-19.
  • Fungal coinfections, including *Cryptococcus neoformans*, may represent an underappreciated threat in severe COVID-19.

Implications:

  • Recognizing and managing fungal coinfections, such as *Cryptococcus neoformans*, is crucial for improving outcomes in severe COVID-19.
  • Further research is needed to understand the epidemiology and clinical impact of fungal reactivation in COVID-19 patients.
  • This case underscores the importance of considering non-bacterial pathogens in the differential diagnosis of worsening respiratory status in severe COVID-19.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
528
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
511
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
418
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
240
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
449